Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 3/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 5/20 | 0.40 |
| ▸ | NPY1R | P25929 | 4/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.39 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369010 | 0.94 | GLP1R (0.45) | GLP1RVIPR1VIPR2BACE1 | |
| SCHEMBL9126106 | 0.92 | VIPR2 (0.45) | GLP1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9126093 | 0.92 | VIPR2 (0.45) | GLP1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29649781 | 0.91 | AGTR2 (0.51) | GLP1RAGTR1AGTR2NPY4RNPY1R | |
| SCHEMBL31538114 | 0.91 | NPY4R (0.42) | GLP1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30839892 | 0.91 | GLP1R (0.45) | GLP1RVIPR1KEAP1 | |
| SCHEMBL29727876 | 0.90 | GLP1R (0.43) | GLP1RENPEPVIPR1VIPR2KEAP1 | |
| SCHEMBL31643038 | 0.89 | GLP1R (0.42) | GLP1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14921120 | 0.88 | VIPR2 (0.44) | GLP1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30866245 | 0.88 | NPY4R (0.42) | GLP1RNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | claimed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | claimed |
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | GIPR, GLP1R, GPR119 | GLP1R 2/4885ENPEP 350/4885AGTR1 287/4885 |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | GIPR, GLP1R, GPR119 | GLP1R 2/4885ENPEP 341/4885AGTR1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.